

10/ 554,202

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	3	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	4	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	5	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	6	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	7	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	8	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	9	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	10	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	11	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	12	JUN 25	CA/CAPplus and USPAT databases updated with IPC reclassification data
NEWS	13	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	14	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	15	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	16	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	17	JUL 28	CA/CAPplus patent coverage enhanced
NEWS	18	JUL 28	EPFULL enhanced with additional legal status information from the epline Register
NEWS	19	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	20	JUL 28	STN Viewer performance improved
NEWS	21	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	22	AUG 13	CA/CAPplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	23	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	24	AUG 15	CAPplus currency for Korean patents enhanced
NEWS	25	AUG 25	CA/CAPplus, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching
NEWS	26	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

10/ 554,202

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:10:44 ON 02 SEP 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:11:00 ON 02 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

```
STRUCTURE FILE UPDATES:      1 SEP 2008   HIGHEST RN 1045602-82-1
DICTIONARY FILE UPDATES:    1 SEP 2008   HIGHEST RN 1045602-82-1
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

```
=>
Uploading C:\Program Files\Stnexp\Queries\10554202.str
```

10/ 554,202



```
chain nodes :
11 19 20 21 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17
chain bonds :
1-19 7-11 11-12 19-20 20-21 21-22
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17
exact/norm bonds :
1-19 7-11 11-12 19-20 21-22
exact bonds :
20-21
normalized bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17
isolated ring systems :
containing 1 : 12 :
```


```
Hydrogen count :
9:= exact 1
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 19:CLASS 20:CLASS
21:CLASS 22:CLASS
```

L1 STRUCTURE UPLOADED

=> d L1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 14:11:32 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1269 TO ITERATE

100.0% PROCESSED 1269 ITERATIONS

411 ANSWERS

SEARCH TIME: 00.00.01

L2 411 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'CAPLUS' ENTERED AT 14:11:37 ON 02 SEP 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Sep 2008 VOL 149 ISS 10

FILE LAST UPDATED: 1 Sep 2008 (20080901/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

10/ 554,202

=> s 12

L3 9 L2

=> d 13 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 9 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:631491 CAPLUS

DOCUMENT NUMBER: 149:44599

TITLE: Discovery of Novel Small-Molecule Inhibitors of Human Epidermal Growth Factor Receptor-2: Combined Ligand and Target-Based Approach

AUTHOR(S): Gundla, Rambabu; Kazemi, Roza; Sanam, Ramadevi; Muttineni, Ravikumar; Sarma, Jagarlapudi A. R. P.; Dayam, Raveendra; Neamati, Nouri

CORPORATE SOURCE: Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA

SOURCE: Journal of Medicinal Chemistry (2008), 51(12), 3367-3377

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Consensus virtual screening models were generated and validated utilizing a set of known human epidermal growth factor receptor-2 (HER2) inhibitors and modeled HER2 active and inactive state structures. The virtual screening models were successfully employed to discover a set of structurally diverse compds. with growth inhibitory activity against HER2-overexpressing SKBR3 breast cancer cell line. A search of a 3D database containing 350000 small-mols. using the consensus models retrieved 531 potential hits. Of the 531 hits, 57 were selected for testing in SKBR3 cells on the basis of structural novelty and desirable drug-like properties. Seven compds. inhibited growth of SKBR3 cells with IC50 values <10 μ M. These lead compds. have desirable physicochem. properties and are excellent candidates for further optimization.


IT 786689-52-9 871019-02-2

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(discovery of novel small-mol. inhibitors of human EGFR-2: combined ligand and target-based approach)


RN 786689-52-9 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyrazinylmethoxy)phenyl]-5-[(1R)-2-(dimethylamino)-1-methylethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 871019-02-2 CAPLUS
 CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:338435 CAPLUS
 DOCUMENT NUMBER: 148:552721
 TITLE: Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase
 AUTHOR(S): Barlaam, Bernard; Acton, David G.; Ballard, Peter; Bradbury, Robert H.; Cross, Darren; Ducray, Richard; Germain, Herve; Hudson, Kevin; Klinowska, Teresa; Magnien, Francoise; Ogilvie, Donald J.; Olivier, Annie; Ross, Helen S.; Smith, Robin; Trigwell, Cath B.; Vautier, Michel; Wright, Lindsay
 CORPORATE SOURCE: Centre de Recherches, Z.I.S.E. La Pompelle, AstraZeneca, Reims, 51689, Fr.

SOURCE: Bioorganic & Medicinal Chemistry Letters (2008),
18(6), 1799-1803
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English


AB We have identified a new series of C-5 substituted
indazolylaminoquinazolines as potent erbB2 kinase inhibitors. The lead
compound 22 showed excellent in vitro potency, good phys. properties,
acceptable oral pharmacokinetics in rat and dog, and low human in vitro
clearance. It showed at least equivalent activity dose for dose compared to
lapatinib in various erbB2- or EGFR-driven xenograft models after chronic
oral administration.

IT 871019-56-6
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT
(Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(neutral 5-substituted 4-indazolylaminoquinazolines as oral inhibitors
of erbB2 receptor TK)

RN 871019-56-6 CAPLUS

CN Propanamide, N,N-dimethyl-2-[[4-[[3-methyl-4-[(6-methyl-3-
pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:85165 CAPLUS

DOCUMENT NUMBER: 148:369248

TITLE: A new series of neutral 5-substituted
4-anilinoquinazolines as potent, orally active
inhibitors of erbB2 receptor tyrosine kinase

AUTHOR(S): Barlaam, Bernard; Ballard, Peter; Bradbury, Robert H.;
Ducray, Richard; Germain, Herve; Hickinson, D. Mark;
Hudson, Kevin; Kettle, Jason G.; Klinowska, Teresa;
Magnien, Francoise; Ogilvie, Donald J.; Olivier,
Annie; Pearson, Stuart E.; Scott, James S.; Suleman,
Abid; Trigwell, Cath B.; Vautier, Michel; Whittaker,
Robin D.; Wood, Robin

CORPORATE SOURCE: Centre de Recherches, AstraZeneca, Reims, 51689, Fr.
SOURCE: Bioorganic & Medicinal Chemistry Letters (2008),
18(2), 674-678
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 148:369248


AB Starting from initial lead 1 containing a basic 5-substituent, optimization of the glycolamide-derived neutral 5-substituent led to potent inhibitors of erbB2 with good pharmacokinetics. Representative compds. 19 and 21 inhibited phosphorylation of erbB2 in a mouse BT474C xenograft model after oral administration.

IT 871018-78-9P 871019-34-0P 871019-56-6P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (anilinoquinazolines as inhibitors of erbB2 receptor tyrosine kinase)

RN 871018-78-9 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N,N-dimethyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-34-0 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-N-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-56-6 CAPLUS

CN Propanamide, N,N-dimethyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 871018-52-9P 871018-67-6P 871018-77-8P
 871018-80-3P 871018-90-5P 871018-91-6P
 871019-24-8P 871019-49-7P 871019-55-5P
 871019-96-4P 871021-07-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(anilinoquinazolines as inhibitors of erbB2 receptor tyrosine kinase)

RN 871018-52-9 CAPLUS


CN Acetamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-
 quinazolinyl]oxy]- (CA INDEX NAME)



RN 871018-67-6 CAPLUS

CN Acetamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-
 quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl- (CA INDEX NAME)


10/ 554,202



RN 871018-77-8 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871018-80-3 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 871018-90-5 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N,N-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871018-91-6 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



10/ 554,202

RN 871019-24-8 CAPLUS


CN Acetamide, N-(2-hydroxyethyl)-N-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)



RN 871019-49-7 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-N-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871019-55-5 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 871019-96-4 CAPLUS

CN Propanamide, N-(2-methoxyethyl)-N-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871021-07-7 CAPLUS

CN Propanamide, N,N-dimethyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

12

THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1170549 CAPLUS

DOCUMENT NUMBER: 147:514416

TITLE: Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase

AUTHOR(S): Ballard, Peter; Barlaam, Bernard C.; Bradbury, Robert H.; Dishington, Allan; Hennequin, Laurent F. A.; Hickinson, D. Mark; Hollingsworth, Ian M.; Kettle, Jason G.; Klinowska, Teresa; Ogilvie, Donald J.; Pearson, Stuart E.; Scott, James S.; Suleman, Abid; Whittaker, Robin; Williams, Emma J.; Wood, Robin; Wright, Lindsay

CORPORATE SOURCE: Cancer and Infection Research, AstraZeneca, Mereside, Macclesfield, SK10 4TG, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(22), 6326-6329

CODEN: BMCLE8; ISSN: 0960-894X


PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 147:514416

GI



I

AB Neutral 5-substituted 4-anilinoquinazolines addressed high in vivo clearance and phospholipidosis associated with previous basic compds. A representative compound 8a (I) inhibited tumor growth in a mouse xenograft model when co-administered with the cytochrome P 450 inhibitor 1-aminobenzotriazole (ABT), and data are consistent with pharmacol. primarily reflecting inhibition of erbB2 receptor tyrosine kinase.


IT 853000-40-5P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(anilinoquinazolines as inhibitors of erbB2 receptor tyrosine kinase)

RN 853000-40-5 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)



IT 853000-46-1P 853000-98-3P 853001-06-6P
853001-08-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(anilinoquinazolines as inhibitors of erbB2 receptor tyrosine kinase)

RN 853000-46-1 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 853000-98-3 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 853001-06-6 CAPLUS

CN Acetamide, N-[(1R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-08-8 CAPLUS


CN Acetamide, N-[(1S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




10/ 554,202

IT 853001-89-5P 853001-92-0P 853002-14-9P
853002-17-2P 956409-93-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(anilinoquinazolines as inhibitors of erbB2 receptor tyrosine kinase)
RN 853001-89-5 CAPLUS
CN Phenol, 2-chloro-4-[[5-[2-(methylamino)ethoxy]-4-quinazolinyl]amino]- (CA
INDEX NAME)



RN 853001-92-0 CAPLUS
CN Phenol, 2-chloro-4-[[5-[(1R)-1-methyl-2-(methyl-2-propen-1-ylamino)ethoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-14-9 CAPLUS
CN Phenol, 2-chloro-4-[[5-[(2R)-2-(methylamino)propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 853002-17-2 CAPLUS

CN Phenol, 2-chloro-4-[[5-[(2S)-2-(methylamino)propoxy]-4-quinazolinyl]amino]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 956409-93-1 CAPLUS

CN Phenol, 2-chloro-4-[[5-[(1S)-1-methyl-2-(methyl-2-propen-1-ylamino)ethoxy]-4-quinazolinyl]amino]-
(CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT:

17


THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:619371 CAPLUS
 DOCUMENT NUMBER: 147:72781
 TITLE: 4-Anilino-substituted quinazoline derivatives as
 tyrosine kinase inhibitors and their preparation,
 pharmaceutical compositions, and use in the treatment
 of cancer
 INVENTOR(S): Barlaam, Bernard Christophe
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 90pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007063291	A1	20070607	WO 2006-GB4447	20061129
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1957499	A1	20080820	EP 2006-808705	20061129
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
PRIORITY APPLN. INFO.:			EP 2005-292552	A 20051202
			EP 2006-290627	A 20060414
			WO 2006-GB4447	W 20061129
OTHER SOURCE(S):	MARPAT 147:72781			
GI				



I



II

AB Quinazoline derivs. I are disclosed. I are medically useful by virtue of an antiproliferative effect, which is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man. In compds. I, R1 is H, OH, alkoxy, or alkoxyalkoxy; R2 and R3 are H, alk(en/yn)yl, or hydroxyalkyl; R4 and R5 are H, alk(en/yn)yl, or alkyl substituted with halo, cyano, OH, (di)(alkyl)amino, or alkoxy; or NR4R5 is saturated N/O/S heterocycle with a 4- to 7-membered ring and optionally substituted by halo, cyano, OH, alkyl, and/or alkoxy; R6 and R7 are H or halo; R8 and R9 are H, halo, cyano, alk(en/yn)yl, or alkoxy; Z is (CH2)0-3 and its alkyl derivs.; Q is alkylthio, alkynyl, or a C-linked, saturated or partially unsatd. 4- to 7-membered heterocycle containing 1 or 2 O atoms and optional substituents selected from F, OH, alkoxy, and alkyl; wherein any heterocyclic NR4R5 or Q may bear 1 or 2 oxo or thioxo groups; including pharmaceutically acceptable salts. Eight examples are given. For instance, etherification of (R)-4-(2-hydroxypropionyl)morpholine with 2-chloro-4-[(5-fluoroquinazolin-4-yl)amino]phenol using NaH in DMA (47%), followed by Mitsunobu reaction with tetrahydrofuran-2-ylmethanol (66%), gave invention compound II. In test for inhibition of protein phosphorylation, II was selective for erbB2 tyrosine kinase over EGFR tyrosine kinase, with IC50 values of 0.008 and 0.362 μ M, resp. II also inhibited proliferation of BT474C human mammary carcinoma cells in vitro, with an IC50 of 0.337 μ M.

IT 940008-97-9P 940008-98-0P 940008-99-1P

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of anilino-substituted quinazolines as tyrosine kinase inhibitors and antiproliferatives)


RN 940008-97-9 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-N-methyl-2-[[4-[[3-methyl-4-[(tetrahydro-2H-pyran-2-yl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX

10/ 554,202

NAME)


Absolute stereochemistry.



RN 940008-98-0 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-[(tetrahydro-2H-pyran-2-yl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 940008-99-1 CAPLUS


CN Propanamide, 2-[[4-[[3-chloro-4-[(tetrahydro-2H-pyran-2-yl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 940009-01-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of anilino-substituted quinazolines as tyrosine
 kinase inhibitors and antiproliferatives)
 RN 940009-01-8 CAPLUS
 CN Propanamide, N-[2-(acetyloxy)ethyl]-N-methyl-2-[[4-[[3-methyl-4-
 [(tetrahydro-2H-pyran-2-yl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]-,
 (2R)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:618627 CAPLUS
 DOCUMENT NUMBER: 147:31138
 TITLE: Preparation of quinazolines as inhibitors of erbB2
 receptor tyrosine kinase
 INVENTOR(S): Bradbury, Robert Hugh; Barlaam, Bernard Christophe;
 Ducray, Richard
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 79pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007063293	A1	20070607	WO 2006-GB4451	20061129
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1960371	A1	20080827	EP 2006-820361	20061129
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			EP 2005-292551	A 20051202
			WO 2006-GB4451	W 20061129
OTHER SOURCE(S):			MARPAT 147:31138	
GI				



AB Title compds. [I; R1 = H, OH, alkoxy, alkoxyalkoxy; R2, R3 = H, alkyl, alkenyl, alkynyl, hydroxyalkyl; R4, R5 = H, alkenyl, alkynyl, (substituted) alkyl; NR4R5 = 4-7 membered (substituted) heterocyclyl; G1, G2 = H, halo; G3, G4 = H, halo, cyano, alkyl, alkoxy, alkenyl, alkynyl; Q1 = atoms to form a 4-8 membered (unsatd.) (substituted) heterocyclyl], were prepared. Thus, (2R)-2-[[4-[[4-(azepan-1-ylcarbonyl)-3-chlorophenyl]amino]quinazolin-5-yl]oxy]-N-(2-hydroxyethyl)-N-methylpropanamide [preparation from (R)-lactamide, 5-fluoroquinazolin-4(3H)-one, 2-methylaminoethanol, 4-amino-2-chlorobenzoic acid, and azepane given] inhibited proliferation of BT474C cells with IC50 = 0.179 μ M.


IT 939427-43-7P 939427-44-8P 939427-45-9P
 939427-46-0P 939427-47-1P 939427-48-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (claimed compound; preparation of quinazolines as inhibitors of erbB2 tyrosine kinase)

RN 939427-43-7 CAPLUS

10/ 554,202

CN Propanamide, 2-[[4-[[3-chloro-4-[(hexahydro-1H-azepin-1-yl)carbonyl]phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 939427-44-8 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(1-piperidinylcarbonyl)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 939427-45-9 CAPLUS


CN Propanamide, 2-[[4-[[3-chloro-4-(1-pyrrolidinylcarbonyl)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 939427-46-0 CAPLUS
 CN Propanamide, 2-[[4-[[3-chloro-4-[(hexahydro-1H-azepin-1-yl)carbonyl]phenyl]amino]-5-quinazolinyl]oxy]-N,N-dimethyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 939427-47-1 CAPLUS
 CN Propanamide, 2-[[4-[[3-chloro-4-(1-piperidinylcarbonyl)phenyl]amino]-5-quinazolinyl]oxy]-N,N-dimethyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 939427-48-2 CAPLUS

10/ 554,202


CN Propanamide, 2-[[4-[[3-chloro-4-(1-pyrrolidinylcarbonyl)phenyl]amino]-5-quinazolinyl]oxy]-N,N-dimethyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 939427-49-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinazolines as inhibitors of erbB2 tyrosine kinase)
RN 939427-49-3 CAPLUS
CN Glycine, N-[(2R)-2-[[4-[[3-chloro-4-[(hexahydro-1H-azepin-1-yl)carbonyl]phenyl]amino]-5-quinazolinyl]oxy]-1-oxopropyl]-N-methyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1313931 CAPLUS
DOCUMENT NUMBER: 144:36370
TITLE: Preparation of 4-anilino-5-carbamoylmethoxyquinazolines as selective erbB2 receptor tyrosine kinase inhibitors for use against tumors
INVENTOR(S): Bradbury, Robert Hugh; Kettle, Jason Grant; Scott, James Stewart; Barlaam, Bernard Christophe
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca Uk Limited
SOURCE: PCT Int. Appl., 268 pp.

CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005118572	A1	20051215	WO 2005-GB2215	20050602
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005250224	A1	20051215	AU 2005-250224	20050602
CA 2567832	A1	20051215	CA 2005-2567832	20050602
EP 1756088	A1	20070228	EP 2005-747243	20050602
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
CN 1993349	A	20070704	CN 2005-80025966	20050602
BR 2005011741	A	20080102	BR 2005-11741	20050602
JP 2008501675	T	20080124	JP 2007-514135	20050602
IN 2006DN07220	A	20070824	IN 2006-DN7220	20061130
US 20070232607	A1	20071004	US 2006-628011	20061130
MX 2006PA14125	A	20070131	MX 2006-PA14125	20061204
NO 2006006081	A	20070220	NO 2006-6081	20061229
KR 2007038500	A	20070410	KR 2007-700221	20070104
PRIORITY APPLN. INFO.:			EP 2004-291393	A 20040604
			WO 2005-GB2215	W 20050602
OTHER SOURCE(S):		CASREACT 144:36370; MARPAT 144:36370		
GI				



AB The invention concerns 4-anilino-5-carbamoylmethoxyquinazolines (shown as I; variables defined below; e.g. 2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]acetamide (shown as II)), processes for their preparation, pharmaceutical compns. containing them and their

use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumors which are sensitive to inhibition of erbB2 receptor tyrosine kinases. For I: m = 0-2; each R1 = hydroxy, (1-6C)alkoxy, (3-7C)cycloalkyloxy and (3-7C)cycloalkyl(1-6C)alkoxy; R2 = H or (1-4C)alkyl; n = 0-4; each R3 = halo, cyano, (1-4C)alkyl, trifluoromethyl, (1-4C)alkoxy, (2-4C)alkenyl and (2-4C)alkynyl; X1 = O, S, SO, SO2, N(R13), CH(OR13), CON(R13), N(R13)CO, SO2N(R13), N(R13)SO2, OC(R13)2, C(R13)2O, SC(R13)2, C(R13)2S, CO, C(R13)2N(R13) and N(R13)C(R13)2 (R13= H or (1-6C)alkyl); Q1 = (un)substituted aryl or heteroaryl. R4 and R5, which may be the same or different, = H and (1-6C)alkyl, or R4 and R5 together with the C atom to which they are attached form a (3-7C)cycloalkyl ring; R6 and R7, which may be the same or different, = H, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl(1-6C)alkyl, heterocyclyl and heterocyclyl(1-6C)alkyl, or R6 and R7 together with the N atom to which they are attached form a saturated 4-7 membered heterocyclic ring which optionally contains ≥ 1 addnl. heteroatoms = O, S, SO, SO2 and NR10; addnl. details are given in the claims. Methods of preparation are claimed and preps. and/or characterization data for .apprx.180 examples of I are included. For example, II was prepared in 13% yield by condensation of 2-bromoacetamide with 4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-ol (preparation given) in DMA in the presence of K2CO3 using 5 min of ultrasound treatment. IC50 values for inhibition of EGFR and erbB2 tyrosine kinase protein phosphorylation are tabulated for 4 examples of I.

IT 871018-52-9P, 2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]acetamide 871018-53-0P

, 2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-methylsulfonylethyl)acetamide 871018-56-3P,
2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-cyclopropylacetamide 871018-57-4P,
2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-cyclobutylacetamide 871018-58-5P, 2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-methoxyethyl)acetamide 871018-59-6P, 2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-ethylacetamide 871018-60-9P, N-Allyl-2-[[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]acetamide 871018-61-0P,
, 2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-ethyl-N-methylacetamide 871018-62-1P,
2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-[2-(morpholin-4-yl)ethyl]acetamide 871018-65-4P,
2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-methyl-N-prop-2-ynylacetamide 871018-67-6P,
2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-hydroxyethyl)-N-methylacetamide 871018-68-7P,
2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-methylsulfonylethyl)-N-methylacetamide 871018-69-8P,
, 2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-methyl-N-(1-methylpiperidin-4-yl)acetamide 871018-70-1P,
, 2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-isopropyl-N-methylacetamide 871018-71-2P,
2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-dimethylaminoethyl)-N-methylacetamide 871018-75-6P,
(2R)-2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871018-77-8P, (2R)-2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-methylpropanamide 871018-78-9P, (2R)-2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N,N-dimethylpropanamide 871018-80-3P, (2R)-2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-hydroxyethyl)-N-methylpropanamide 871018-86-9P,
(2S)-2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871018-89-2P, (2S)-2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-methylpropanamide 871018-90-5P, (2S)-2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N,N-dimethylpropanamide 871018-91-6P, (2S)-2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-hydroxyethyl)-N-methylpropanamide 871018-95-0P,
(2R)-2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-4-hydroxy-N-methylbutanamide 871018-96-1P,
(2R)-2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-4-hydroxy-N-(2-hydroxy-1,1-dimethylethyl)butanamide 871018-97-2P, (2R)-2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-4-hydroxy-N,N-dimethylbutanamide 871018-98-3P, (2R)-2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-4-hydroxy-N-(2-hydroxyethyl)-N-methylbutanamide 871019-02-2P,
2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-2-methylpropanamide 871019-03-3P, 2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-methyl-2-methylpropanamide 871019-06-6P, 2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-hydroxy-1,1-dimethylethyl)-2-methylpropanamide 871019-07-7P,
2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-hydroxyethyl)-2-methylpropanamide 871019-08-8P,

2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N,N-bis(2-hydroxyethyl)-2-methylpropanamide 871019-09-9P
, 2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-hydroxyethyl)-N-methyl-2-methylpropanamide
871019-11-3P, N-(2-Hydroxyethyl)-2-methyl-2-[[4-[[3-methyl-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide
871019-16-8P, N-Methyl-2-methyl-2-[[4-[[3-methyl-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide
871019-17-9P, 2-[[4-[[3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]acetamide 871019-22-6P,
N-(2-Hydroxyethyl)-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]acetamide 871019-23-7P,
N-Methyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]acetamide 871019-24-8P,
N-(2-Hydroxyethyl)-N-methyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]acetamide 871019-28-2P,
(2S)-2-[[4-[[3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-31-7P, (2R)-2-[[4-[[3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide
871019-34-0P, (2R)-N-(2-Hydroxyethyl)-N-methyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide
871019-35-1P, 2-Methyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-38-4P
, N-Methyl-2-methyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-41-9P
, (2R)-N-Methyl-2-[[4-[[3-methyl-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide
871019-42-0P, (2R)-N-(2-Hydroxyethyl)-N-methyl-2-[[4-[[3-methyl-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide
871019-44-2P, 2-Methyl-2-[[4-[[3-methyl-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide
871019-45-3P, N-(2-Hydroxyethyl)-2-methyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide
871019-46-4P, N-(2-Hydroxyethyl)-N-methyl-2-methyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide
871019-47-5P, (2S)-N-Methyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide
871019-48-6P, (2S)-N-(2-Hydroxyethyl)-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide
871019-49-7P, (2S)-N-(2-Hydroxyethyl)-N-methyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide
871019-54-4P, (2R)-N-Methyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-55-5P
, (2R)-N-(2-Hydroxyethyl)-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-56-6P
, (2R)-N,N-Dimethyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-57-7P
, (2R)-N-Isopropyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-58-8P
, (2R)-N-Ethyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-59-9P
, (2R)-N-[2-(Diethylamino)ethyl]-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-60-2P
, (2R)-N-[2-(Dimethylamino)ethyl]-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-61-3P
, (2R)-N-Cyclopropyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-62-4P
, (2R)-N-(3-Hydroxypropyl)-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-63-5P
, (2R)-N-(2-Methoxyethyl)-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-


yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-64-6P
 , (2R)-2-[[4-[[3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-[2-(morpholin-4-yl)ethyl]propanamide 871019-65-7P, (2R)-2-[[4-[[3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-[2-(pyrrolidin-1-yl)ethyl]propanamide 871019-66-8P, (2R)-N-[2-(Acetylamino)ethyl]-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-67-9P
 , (2R)-2-[[4-[[3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-[3-(4-methylpiperazin-1-yl)propyl]propanamide 871019-68-0P, (2R)-2-[[4-[[3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-[3-(2-oxopyrrolidin-1-yl)propyl]propanamide 871019-69-1P,
 (2R)-2-[[4-[[3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-[2-(methylthio)ethyl]propanamide 871019-70-4P,
 (2R)-N-(3-Methoxypropyl)-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-71-5P
 , (2R)-N-Cyclobutyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-72-6P
 , (2R)-N-((2R)-2-Hydroxypropyl)-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-73-7P
 , (2R)-N-((2S)-2-Hydroxypropyl)-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-74-8P
 , (2R)-N-((2S)-2,3-Dihydroxypropyl)-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-75-9P
 , (2R)-N-((1R)-2-Hydroxy-1-methylethyl)-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-76-0P, (2R)-N-((1S)-2-Hydroxy-1-methylethyl)-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-78-2P, (2R)-N-[2-(Dimethylamino)ethyl]-N-methyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-83-9P
 , (2R)-N,N-Bis(2-hydroxyethyl)-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-84-0P
 , (2R)-N-Ethyl-N-(2-hydroxyethyl)-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-85-1P
 , (2R)-N,N-Bis(2-methoxyethyl)-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-96-4P
 , (2R)-N-(2-Methoxyethyl)-N-methyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-97-5P
 , (2R)-N,N-Diethyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-99-7P
 , (2R)-N-(3-Hydroxypropyl)-N-methyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871020-45-0P
 , (2R)-N-(2-Hydroxyethyl)-2-[[4-[[3-methoxy-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-methylpropanamide 871020-50-7P, (2R)-2-[[4-[[3-Methoxy-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N,N-dimethylpropanamide 871020-51-8P, (2R)-N-Ethyl-2-[[4-[[3-methoxy-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871020-52-9P
 , (2R)-N-(2-Hydroxyethyl)-2-[[4-[[3-methoxy-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871020-55-2P
 , (2R)-N-(2-Methoxyethyl)-2-[[4-[[3-methoxy-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-methylpropanamide 871020-60-9P, (2R)-N,N-Dimethyl-2-[[4-[[3-methyl-4-[(pyridin-2-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871020-61-0P
 , (2R)-N-Ethyl-2-[[4-[[3-methyl-4-[(pyridin-2-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871020-62-1P
 , (2R)-N-(2-Hydroxyethyl)-2-[[4-[[3-methyl-4-[(pyridin-2-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871020-63-2P

, (2R)-N-(2-Hydroxyethyl)-N-methyl-2-[[4-[[3-methyl-4-[(pyridin-2-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871020-69-8P
 , (2R)-N-(2-Methoxyethyl)-N-methyl-2-[[4-[[3-methyl-4-[(pyridin-2-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871020-90-5P
 , (2R)-2-[[4-[[3-Chloro-4-[(pyridin-2-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N,N-dimethylpropanamide 871020-91-6P,
 (2R)-2-[[4-[[3-Chloro-4-[(pyridin-2-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-hydroxyethyl)-N-methylpropanamide 871020-92-7P,
 (2R)-2-[[4-[[3-Chloro-4-[(pyridin-2-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-hydroxyethyl)propanamide 871020-93-8P,
 (2R)-2-[[4-[[3-Chloro-4-[(pyridin-2-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-ethyl-N-(2-hydroxyethyl)propanamide 871021-02-2P,
 (2R)-2-[[4-[[3-Chloro-4-[(pyridin-2-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-methoxyethyl)-N-methylpropanamide 871021-07-7P,
 (2S)-N,N-Dimethyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871021-08-8P
 , (2R)-2-[[4-[[3-Chloro-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-hydroxyethyl)-N-methylpropanamide 871021-12-4P, (2R)-2-[[4-[[3-Chloro-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N,N-dimethylpropanamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 4-anilino-5-carbamoylmethoxyquinazolines as selective erbB2 receptor tyrosine kinase inhibitors for use against tumors)

RN 871018-52-9 CAPLUS


CN Acetamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)



RN 871018-53-0 CAPLUS


CN Acetamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-[2-(methylsulfonyl)ethyl]- (CA INDEX NAME)

10/ 554,202




RN 871018-56-3 CAPLUS

CN Acetamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-cyclopropyl- (CA INDEX NAME)




RN 871018-57-4 CAPLUS

CN Acetamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-cyclobutyl- (CA INDEX NAME)




RN 871018-58-5 CAPLUS
 CN Acetamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 871018-59-6 CAPLUS
 CN Acetamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-ethyl- (CA INDEX NAME)

10/ 554,202



RN 871018-60-9 CAPLUS


CN Acetamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-2-propen-1-yl- (CA INDEX NAME)



RN 871018-61-0 CAPLUS


CN Acetamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-ethyl-N-methyl- (CA INDEX NAME)

10/ 554,202




RN 871018-62-1 CAPLUS

CN Acetamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 871018-65-4 CAPLUS


CN Acetamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-methyl-N-2-propyn-1-yl- (CA INDEX NAME)




RN 871018-67-6 CAPLUS
 CN Acetamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl- (CA INDEX NAME)



RN 871018-68-7 CAPLUS
 CN Acetamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-methyl-N-[2-(methylsulfonyl)ethyl]- (CA INDEX NAME)




RN 871018-69-8 CAPLUS
 CN Acetamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 871018-70-1 CAPLUS
 CN Acetamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-methyl-N-(1-methylethyl)- (CA INDEX NAME)

10/ 554,202




RN 871018-71-2 CAPLUS
CN Acetamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-[2-(dimethylamino)ethyl]-N-methyl- (CA INDEX NAME)



RN 871018-75-6 CAPLUS
CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 871018-77-8 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871018-78-9 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N,N-dimethyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




10/ 554,202

RN 871018-80-3 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871018-86-9 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871018-89-2 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 871018-90-5 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N,N-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871018-91-6 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




10/ 554,202

RN 871018-95-0 CAPLUS

CN Butanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-4-hydroxy-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871018-96-1 CAPLUS

CN Butanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-4-hydroxy-N-(2-hydroxy-1,1-dimethylethyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871018-97-2 CAPLUS

CN Butanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-4-hydroxy-N,N-dimethyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871018-98-3 CAPLUS

CN Butanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-4-hydroxy-N-(2-hydroxyethyl)-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 871019-02-2 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-2-methyl- (CA INDEX NAME)


10/ 554,202




RN 871019-03-3 CAPLUS
 CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N,2-dimethyl- (CA INDEX NAME)



RN 871019-06-6 CAPLUS
 CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxy-1,1-dimethylethyl)-2-methyl- (CA INDEX NAME)




RN 871019-07-7 CAPLUS
 CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-2-methyl- (CA INDEX NAME)




RN 871019-08-8 CAPLUS
 CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N,N-bis(2-hydroxyethyl)-2-methyl- (CA INDEX NAME)

10/ 554,202




RN 871019-09-9 CAPLUS
 CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N,2-dimethyl- (CA INDEX NAME)




RN 871019-11-3 CAPLUS
 CN Propanamide, N-(2-hydroxyethyl)-2-methyl-2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)

10/ 554,202




RN 871019-16-8 CAPLUS
 CN Propanamide, N,2-dimethyl-2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)




RN 871019-17-9 CAPLUS
 CN Acetamide, 2-[[4-[[3-methyl-4-(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)

10/ 554,202




RN 871019-22-6 CAPLUS
 CN Acetamide, N-(2-hydroxyethyl)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)




RN 871019-23-7 CAPLUS
 CN Acetamide, N-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)

10/ 554,202



RN 871019-24-8 CAPLUS

CN Acetamide, N-(2-hydroxyethyl)-N-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)




RN 871019-28-2 CAPLUS

CN Propanamide, 2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 871019-31-7 CAPLUS

CN Propanamide, 2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-34-0 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-N-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-35-1 CAPLUS


CN Propanamide, 2-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-

pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)



RN 871019-38-4 CAPLUS


CN Propanamide, N,2-dimethyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)



RN 871019-41-9 CAPLUS

CN Propanamide, N-methyl-2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-42-0 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-N-methyl-2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 871019-44-2 CAPLUS

CN Propanamide, 2-methyl-2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)

10/ 554,202




RN 871019-45-3 CAPLUS
 CN Propanamide, N-(2-hydroxyethyl)-2-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)



RN 871019-46-4 CAPLUS
 CN Propanamide, N-(2-hydroxyethyl)-N,2-dimethyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)


10/ 554,202



RN 871019-47-5 CAPLUS

CN Propanamide, N-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871019-48-6 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 871019-49-7 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-N-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-54-4 CAPLUS

CN Propanamide, N-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871019-55-5 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-2-[[4-[[3-methyl-4-[(6-methyl-3-

10/ 554,202

pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-56-6 CAPLUS

CN Propanamide, N,N-dimethyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-57-7 CAPLUS

CN Propanamide, N-(1-methylethyl)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




10/ 554,202

RN 871019-58-8 CAPLUS

CN Propanamide, N-ethyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-59-9 CAPLUS

CN Propanamide, N-[2-(diethylamino)ethyl]-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871019-60-2 CAPLUS

CN Propanamide, N-[2-(dimethylamino)ethyl]-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 871019-61-3 CAPLUS

CN Propanamide, N-cyclopropyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-62-4 CAPLUS

CN Propanamide, N-(3-hydroxypropyl)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871019-63-5 CAPLUS

CN Propanamide, N-(2-methoxyethyl)-2-[[4-[[3-methyl-4-[(6-methyl-3-

10/ 554,202

pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-64-6 CAPLUS

CN Propanamide, 2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-N-[2-(4-morpholinyl)ethyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-65-7 CAPLUS

CN Propanamide, 2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-66-8 CAPLUS

CN Propanamide, N-[2-(acetamino)ethyl]-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-67-9 CAPLUS

CN Propanamide, 2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




10/ 554,202

RN 871019-68-0 CAPLUS

CN Propanamide, 2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-69-1 CAPLUS

CN Propanamide, 2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-N-[2-(methylthio)ethyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-70-4 CAPLUS

CN Propanamide, N-(3-methoxypropyl)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-71-5 CAPLUS

CN Propanamide, N-cyclobutyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-72-6 CAPLUS

CN Propanamide, N-[(2R)-2-hydroxypropyl]-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871019-73-7 CAPLUS

CN Propanamide, N-[(2S)-2-hydroxypropyl]-2-[[4-[[3-methyl-4-[(6-methyl-3-

10/ 554,202

pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-74-8 CAPLUS

CN Propanamide, N-[(2S)-2,3-dihydroxypropyl]-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871019-75-9 CAPLUS

CN Propanamide, N-[(1R)-2-hydroxy-1-methylethyl]-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 871019-76-0 CAPLUS

CN Propanamide, N-[(1S)-2-hydroxy-1-methylethyl]-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-78-2 CAPLUS

CN Propanamide, N-[2-(dimethylamino)ethyl]-N-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




10/ 554,202

RN 871019-83-9 CAPLUS

CN Propanamide, N,N-bis(2-hydroxyethyl)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-84-0 CAPLUS

CN Propanamide, N-ethyl-N-(2-hydroxyethyl)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871019-85-1 CAPLUS

CN Propanamide, N,N-bis(2-methoxyethyl)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 871019-96-4 CAPLUS

CN Propanamide, N-(2-methoxyethyl)-N-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-97-5 CAPLUS

CN Propanamide, N,N-diethyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871019-99-7 CAPLUS

CN Propanamide, N-(3-hydroxypropyl)-N-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-

pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871020-45-0 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-2-[[4-[[3-methoxy-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-N-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871020-50-7 CAPLUS

CN Propanamide, 2-[[4-[[3-methoxy-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-N,N-dimethyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 871020-51-8 CAPLUS

CN Propanamide, N-ethyl-2-[[4-[[3-methoxy-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871020-52-9 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-2-[[4-[[3-methoxy-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871020-55-2 CAPLUS

CN Propanamide, N-(2-methoxyethyl)-2-[[4-[[3-methoxy-4-[(6-methyl-3-

10/ 554,202

pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871020-60-9 CAPLUS

CN Propanamide, N,N-dimethyl-2-[[4-[[3-methyl-4-(2-pyridinyloxy)phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871020-61-0 CAPLUS

CN Propanamide, N-ethyl-2-[[4-[[3-methyl-4-(2-pyridinyloxy)phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 871020-62-1 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-2-[[4-[[3-methyl-4-(2-pyridinyloxy)phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871020-63-2 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-N-methyl-2-[[4-[[3-methyl-4-(2-pyridinyloxy)phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871020-69-8 CAPLUS

CN Propanamide, N-(2-methoxyethyl)-N-methyl-2-[[4-[[3-methyl-4-(2-

10/ 554,202

pyridinyloxy)phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871020-90-5 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinyloxy)phenyl]amino]-5-quinazolinyl]oxy]-N,N-dimethyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871020-91-6 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinyloxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




10/ 554,202

RN 871020-92-7 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinyloxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871020-93-8 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinyloxy)phenyl]amino]-5-quinazolinyl]oxy]-N-ethyl-N-(2-hydroxyethyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871021-02-2 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinyloxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-methoxyethyl)-N-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 871021-07-7 CAPLUS

CN Propanamide, N,N-dimethyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871021-08-8 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871021-12-4 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-

quinazolinyl]oxy]-N,N-dimethyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:490358 CAPLUS

DOCUMENT NUMBER: 143:43897

TITLE: Preparation of quinazoline derivatives as erbB2 receptor tyrosine kinase inhibitors

INVENTOR(S): Bradbury, Robert Hugh; Hennequin, Laurent Francois Andre; Kettle, Jason Grant

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 286 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051923	A1	20050609	WO 2004-GB4761	20041111
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004293250	A1	20050609	AU 2004-293250	20041111
CA 2545262	A1	20050609	CA 2004-2545262	20041111
EP 1685116	A1	20060802	EP 2004-798484	20041111
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS			
CN 1906178	A	20070131	CN 2004-80040415	20041111
BR 2004016479	A	20070306	BR 2004-16479	20041111
JP 2007511491	T	20070510	JP 2006-538946	20041111

MX 2006PA05364	A	20060731	MX 2006-PA5364	20060512
NO 2006002353	A	20060809	NO 2006-2353	20060523
IN 2006DN03254	A	20070824	IN 2006-DN3254	20060606
US 20070244136	A1	20071018	US 2007-578663	20070117
PRIORITY APPLN. INFO.:			GB 2003-26459	A 20031113
			WO 2004-GB4761	W 20041111
OTHER SOURCE(S):		CASREACT 143:43897; MARPAT 143:43897		
GI				



AB Title compds. I [$m = 0-2$; R_1 independently = OH, (un)substituted-alkoxy, -cycloalkyloxy, etc.; R_2 = H, alkyl; $n = 0-4$; R_3 independently = CN, halo, CF_3 , etc.; $X = O, S, SO$, etc.; Q = (un)substituted-aryl, -heteroaryl; R_4, R_{4a}, R_5, R_{5a} independently = H, (un)substituted-alkyl, or R_4 and R_{4a} together = 3- to 7-membered (un)substituted cycloalkyl ring or R_5 and R_{5a} together = 3- to 7-membered (un)substituted cycloalkyl ring; R_6 = H, alkenyl, alkynyl, etc.; $A = H, Z-(CR_7R_8)_p-$, R_9 ; $p = 1-4$; R_7 and R_8 independently = H, alkyl, alkenyl, etc. or R_7 and R_8 together = (un)substituted-3- to 7-membered-cycloalkyl or -cycloalkenyl ring; $Z = H$, alkylsulfonyl, alkanesulfonylamino, etc.; $R_9 = H, OR_{10}, NR_{11}R_{12}$, etc.; $R_{10} =$ alkyl, alkenyl, alkynyl; R_{11} and R_{12} independently = H, alkyl, alkoxy, carbonyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of erbB2 receptor tyrosine kinase. Thus, e.g., II was prepared by chlorination of 5-fluoro-3,4-dihydro-3H-quinazolin-4-one followed by amination with 3-chloro-4-(2-pyridylmethoxy)aniline to give N-[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-fluoroquinazolin-4-amine (III). III was then converted into the resp. 5-(2-methylamino)ethoxy ether intermediate using 2-(methylamino)ethanol and subsequent acetylation of this intermediate yielded II. The inhibitory activity of I was evaluated using phosphorylation assays of

erbB2 tyrosine kinase and it revealed that selected compds. of the invention displayed IC₅₀ values in the range of 0.002 up to 0.017 μ M. I as inhibitors of erbB2 receptor tyrosine kinase should prove useful as antitumor agents. Pharmaceutical compns. comprising I are disclosed.

IT 853000-27-8P 853000-28-9P 853000-29-0P
853000-30-3P 853000-31-4P 853000-32-5P
853000-33-6P 853000-34-7P 853000-35-8P
853000-36-9P 853000-37-0P 853000-38-1P
853000-39-2P 853000-40-5P 853000-41-6P
853000-42-7P 853000-43-8P 853000-44-9P
853000-45-0P 853000-46-1P 853000-47-2P
853000-48-3P 853000-49-4P 853000-50-7P
853000-51-8P 853000-52-9P 853000-53-0P
853000-54-1P 853000-55-2P 853000-56-3P
853000-57-4P 853000-58-5P 853000-59-6P
853000-60-9P 853000-61-0P 853000-62-1P
853000-63-2P 853000-64-3P 853000-65-4P
853000-66-5P 853000-67-6P 853000-68-7P
853000-69-8P 853000-70-1P 853000-72-3P
853000-73-4P 853000-74-5P 853000-75-6P
853000-76-7P 853000-77-8P 853000-78-9P
853000-79-0P 853000-80-3P 853000-81-4P
853000-82-5P 853000-83-6P 853000-84-7P
853000-85-8P 853000-86-9P 853000-87-0P
853000-88-1P 853000-89-2P 853000-90-5P
853000-91-6P 853000-92-7P 853000-93-8P
853000-94-9P 853000-95-0P 853000-96-1P
853000-97-2P 853000-98-3P 853000-99-4P
853001-00-0P 853001-01-1P 853001-02-2P
853001-03-3P 853001-04-4P 853001-05-5P
853001-06-6P 853001-07-7P 853001-08-8P
853001-09-9P 853001-10-2P 853001-11-3P
853001-12-4P 853001-13-5P 853001-14-6P
853001-15-7P 853001-16-8P 853001-17-9P
853001-18-0P 853001-19-1P 853001-20-4P
853001-21-5P 853001-22-6P 853001-23-7P
853001-24-8P 853001-25-9P 853001-26-0P
853001-27-1P 853001-28-2P 853001-29-3P
853001-30-6P 853001-31-7P 853001-32-8P
853001-33-9P 853001-34-0P 853001-35-1P
853001-36-2P 853001-37-3P 853001-38-4P
853001-39-5P 853001-41-9P 853001-42-0P
853001-43-1P 853001-44-2P 853001-45-3P
853001-46-4P 853001-47-5P 853001-48-6P
853001-49-7P 853001-50-0P 853001-51-1P
853001-52-2P 853001-53-3P 853001-54-4P
853001-55-5P 853001-56-6P 853001-57-7P
853001-58-8P 853001-59-9P 853001-60-2P
853001-61-3P 853001-62-4P 853001-63-5P
853001-64-6P 853001-65-7P 853001-66-8P
853001-67-9P 853001-68-0P 853001-69-1P
853001-70-4P 853001-71-5P 853001-72-6P
853001-73-7P 853001-74-8P 853001-75-9P
853001-76-0P 853001-77-1P 853001-78-2P
853001-79-3P 853001-80-6P 853193-87-0P, AZ
12240261


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazoline derivs. as erbB2 receptor tyrosine kinase

inhibitors)


RN 853000-27-8 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)



RN 853000-28-9 CAPLUS


CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-methoxy-N-methyl- (CA INDEX NAME)



RN 853000-29-0 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-(dimethylamino)-N-methyl- (CA INDEX NAME)


10/ 554,202



RN 853000-30-3 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-methoxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 853000-31-4 CAPLUS

CN Acetamide, N-[(1R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-methoxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 853000-32-5 CAPLUS

CN Acetamide, N-[(1R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 853000-33-6 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)


10/ 554,202



RN 853000-34-7 CAPLUS


CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 853000-35-8 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)




RN 853000-36-9 CAPLUS
 CN Acetamide, 2-hydroxy-N-methyl-N-[2-[[4-[[3-methyl-4-(2-pyrazinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)




RN 853000-37-0 CAPLUS
 CN Acetamide, 2-hydroxy-N-methyl-N-[2-[[4-[[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

10/ 554,202



RN 853000-38-1 CAPLUS


CN Acetamide, 2-hydroxy-N-methyl-N-[2-[[4-[[3-methyl-4-[(5-methyl-3-isoxazolyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)



RN 853000-39-2 CAPLUS


CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-methoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 853000-40-5 CAPLUS


CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)




RN 853000-41-6 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)


10/ 554,202




RN 853000-42-7 CAPLUS
 CN Acetamide, N-[2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)



RN 853000-43-8 CAPLUS
 CN Acetamide, N-[2-[[4-[[3-chloro-4-[(6-methyl-2-pyridinyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)




RN 853000-44-9 CAPLUS
 CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyrazinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)



RN 853000-45-0 CAPLUS
 CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 853000-46-1 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853000-47-2 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyrazinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




10/ 554,202

RN 853000-48-3 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-[(6-methyl-2-pyridinyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853000-49-4 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.




RN 853000-50-7 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 853000-51-8 CAPLUS
 CN Acetamide, N-[2-[[4-[[3-chloro-4-[(6-methyl-2-pyridinyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)




RN 853000-52-9 CAPLUS
 CN Acetamide, N-[2-[[4-[[3-chloro-4-[(2-fluorophenyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)

10/ 554,202




RN 853000-53-0 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)




RN 853000-54-1 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)




RN 853000-55-2 CAPLUS
 CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyrazinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)




RN 853000-56-3 CAPLUS
 CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 853000-57-4 CAPLUS


CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-ethyl- (CA INDEX NAME)




RN 853000-58-5 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-ethyl-2-hydroxy- (CA INDEX NAME)

10/ 554,202




RN 853000-59-6 CAPLUS
 CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-propyl- (CA INDEX NAME)




RN 853000-60-9 CAPLUS
 CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-propyl- (CA INDEX NAME)

10/ 554,202




RN 853000-61-0 CAPLUS
CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-(1-methylethyl)- (CA INDEX NAME)




RN 853000-62-1 CAPLUS
CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-(1-methylethyl)- (CA INDEX NAME)

10/ 554,202




RN 853000-63-2 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-2-propen-1-yl- (CA INDEX NAME)




RN 853000-64-3 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-2-propen-1-yl- (CA INDEX NAME)




RN 853000-65-4 CAPLUS
 CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-cyclopropyl- (CA INDEX NAME)




RN 853000-66-5 CAPLUS
 CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-cyclopropyl-2-hydroxy- (CA INDEX NAME)

10/ 554,202



RN 853000-67-6 CAPLUS


CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 853000-68-7 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-(cyclopropylmethyl)-2-hydroxy- (CA INDEX NAME)


10/ 554,202



RN 853000-69-8 CAPLUS
 CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-cyclobutyl- (CA INDEX NAME)




RN 853000-70-1 CAPLUS
 CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-cyclobutyl-2-hydroxy- (CA INDEX NAME)



RN 853000-72-3 CAPLUS


CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 853000-73-4 CAPLUS


CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)

10/ 554,202



RN 853000-74-5 CAPLUS


CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 853000-75-6 CAPLUS


CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-(2-hydroxyethyl)- (CA INDEX NAME)

10/ 554,202



RN 853000-76-7 CAPLUS


CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 853000-77-8 CAPLUS


CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-(2-methoxyethyl)- (CA INDEX NAME)

10/ 554,202




RN 853000-78-9 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 853000-79-0 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 853000-80-3 CAPLUS
 CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-2-propyn-1-yl- (CA INDEX NAME)




RN 853000-81-4 CAPLUS
 CN Propanamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

10/ 554,202




RN 853000-82-5 CAPLUS

CN 2-Furancarboxamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]tetrahydro-N-methyl- (CA INDEX NAME)




RN 853000-83-6 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N,1-dimethyl- (CA INDEX NAME)



RN 853000-84-7 CAPLUS
 CN Propanamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N,2-dimethyl- (CA INDEX NAME)




RN 853000-85-8 CAPLUS
 CN Cyclopropanecarboxamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-1-hydroxy-N-methyl- (CA INDEX NAME)



RN 853000-86-9 CAPLUS


CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-methyl-2-(methyamino)- (CA INDEX NAME)



RN 853000-87-0 CAPLUS

CN Propanamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-(hydroxymino)-N,N-dimethyl- (CA INDEX NAME)


10/ 554,202



RN 853000-88-1 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853000-89-2 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 853000-90-5 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-(dimethylamino)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853000-91-6 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-methoxy- (CA INDEX NAME)

Absolute stereochemistry.




10/ 554,202

RN 853000-92-7 CAPLUS


CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 853000-93-8 CAPLUS


CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy- (CA INDEX NAME)



RN 853000-94-9 CAPLUS


CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-(dimethylamino)- (CA INDEX NAME)

10/ 554,202



RN 853000-95-0 CAPLUS


CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-methoxy- (CA INDEX NAME)



RN 853000-96-1 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-(methylsulfonyl)- (CA INDEX NAME)


10/ 554,202



RN 853000-97-2 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 853000-98-3 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 853000-99-4 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-(dimethylamino)-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-00-0 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-methoxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




10/ 554,202

RN 853001-01-1 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-N-methyl-2-(methylsulfonyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-02-2 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyrazinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-03-3 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-04-4 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-05-5 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-[(2-fluorophenyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




10/ 554,202

RN 853001-06-6 CAPLUS

CN Acetamide, N-[(1R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-07-7 CAPLUS

CN Acetamide, N-[(1R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-08-8 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 853001-09-9 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-10-2 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-methoxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




10/ 554,202

RN 853001-11-3 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-12-4 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-13-5 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 853001-14-6 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-(dimethylamino)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-15-7 CAPLUS

CN Butanamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2,4-dihydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




10/ 554,202

RN 853001-16-8 CAPLUS

CN Butanamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2,4-dihydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-17-9 CAPLUS

CN Butanamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2,4-dihydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-18-0 CAPLUS

CN Butanamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2,4-dihydroxy-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-19-1 CAPLUS

CN Butanamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2,4-dihydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-20-4 CAPLUS

CN Butanamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2,4-dihydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




10/ 554,202

RN 853001-21-5 CAPLUS

CN Butanamide, N-[(1R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2,4-dihydroxy-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-22-6 CAPLUS

CN Butanamide, N-[(1R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2,4-dihydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-23-7 CAPLUS

CN Butanamide, N-[2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2,4-dihydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 853001-24-8 CAPLUS

CN Butanamide, N-[2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2,4-dihydroxy-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-25-9 CAPLUS

CN Butanamide, N-[(1R)-2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2,4-dihydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-26-0 CAPLUS

CN Butanamide, N-[(1R)-2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-


quinazolinyl]oxy]-1-methylethyl]-2,4-dihydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 853001-27-1 CAPLUS


CN Acetamide, N-methyl-N-[2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)



RN 853001-28-2 CAPLUS


Acetamide, N-methyl-N-[2-[4-[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino
]-5-quinazolinyl]oxy]ethyl)- (CA INDEX NAME)

10/ 554,202



RN 853001-29-3 CAPLUS


CN Acetamide, N-methyl-N-[2-[[4-[[3-methyl-4-[(5-methyl-3-isoxazolyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)



RN 853001-30-6 CAPLUS


CN Acetamide, 2-hydroxy-N-methyl-N-[2-[[4-[[3-methyl-4-(2-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

10/ 554,202



RN 853001-31-7 CAPLUS


CN Acetamide, 2-hydroxy-N-[2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)



RN 853001-32-8 CAPLUS


CN Acetamide, 2-hydroxy-N-[2-[[4-[[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

10/ 554,202



RN 853001-33-9 CAPLUS


CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1,1-dimethylethyl]-2-hydroxy- (CA INDEX NAME)



RN 853001-34-0 CAPLUS

CN Acetamide, 2-hydroxy-N-[(2R)-2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-35-1 CAPLUS

CN Acetamide, 2-hydroxy-N-[(2R)-2-[[4-[[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-36-2 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[4-[(3-fluorophenyl)methoxy]-3-methylphenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.




10/ 554,202

RN 853001-37-3 CAPLUS

CN Acetamide, 2-hydroxy-N-[(2R)-2-[[4-[[3-methyl-4-(2-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-38-4 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-39-5 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 853001-41-9 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[4-(3-fluorophenyl)methoxy]-3-methylphenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-42-0 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-methyl-4-(2-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-43-1 CAPLUS

10/ 554,202

CN Acetamide, 2-hydroxy-N-methyl-N-[(2R)-2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-44-2 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(2R)-2-[[4-[[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-45-3 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(2R)-2-[[4-[[3-methyl-4-(5-methyl-3-isoxazolyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-46-4 CAPLUS

CN Acetamide, N-methyl-N-[(1R)-1-methyl-2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-47-5 CAPLUS

Acetamide, N-methyl-N-[(1R)-1-methyl-2-[[4-[[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




10/ 554,202

RN 853001-48-6 CAPLUS

CN Acetamide, N-[(1R)-2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-49-7 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(1R)-1-methyl-2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-50-0 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(1R)-1-methyl-2-[[4-[[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-51-1 CAPLUS

CN Cyclopropanecarboxamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-1-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-52-2 CAPLUS

CN Propanamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




10/ 554,202

RN 853001-53-3 CAPLUS

CN Propanamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-54-4 CAPLUS

CN Propanamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-55-5 CAPLUS

CN Propanamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-methoxy-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-56-6 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-57-7 CAPLUS

CN Acetamide, N-methyl-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-58-8 CAPLUS

10/ 554,202

CN Acetamide, 2-(dimethylamino)-N-methyl-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-59-9 CAPLUS

CN 1-Pyrrolidineacetamide, N-methyl-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-60-2 CAPLUS

CN 4-Morpholineacetamide, N-methyl-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 853001-61-3 CAPLUS

CN 1-Piperazineacetamide, N,4-dimethyl-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-62-4 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(2S)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-63-5 CAPLUS

CN Acetamide, N-methyl-N-[(2S)-2-[[4-[[3-methyl-4-[(6-methyl-3-

10/ 554,202

pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-64-6 CAPLUS

CN 1-Pyrrolidineacetamide, N-methyl-N-[(2S)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-65-7 CAPLUS

CN Butanamide, 2,4-dihydroxy-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 853001-66-8 CAPLUS

CN Butanamide, 4-bromo-2-hydroxy-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-67-9 CAPLUS

CN Urea, N-(2-chloroethyl)-N'-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-68-0 CAPLUS

10/ 554,202

CN Acetamide, 2-hydroxy-N-methyl-N-[(1R)-1-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-69-1 CAPLUS

CN Acetamide, N-methyl-N-[(1R)-1-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-70-4 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(1S)-1-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 853001-71-5 CAPLUS

CN Acetamide, N-methyl-N-[(1S)-1-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-72-6 CAPLUS


CN Carbamic acid, [2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]methyl-, methyl ester (9CI) (CA INDEX NAME)

10/ 554,202



RN 853001-73-7 CAPLUS


CN Urea, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N,N'-dimethyl- (CA INDEX NAME)



RN 853001-74-8 CAPLUS

CN Urea, N'-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)


10/ 554,202



RN 853001-75-9 CAPLUS

CN Urea, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-N'-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-76-0 CAPLUS

CN Carbamic acid, [2-[[[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]amino]-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-77-1 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-(methylamino)- (CA INDEX NAME)


Absolute stereochemistry.




RN 853001-78-2 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)


10/ 554,202




RN 853001-79-3 CAPLUS
 CN Acetamide, N-methyl-N-[2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)



RN 853001-80-6 CAPLUS
 CN Acetamide, N-[2-[[4-[[3-chloro-4-[1-methyl-1-(2-pyridinyl)ethoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)



RN 853193-87-0 CAPLUS
 CN Propanamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-3-hydroxy-N-methyl- (CA INDEX NAME)



IT 786689-48-3P 786689-66-5P 786689-86-9P
 853001-81-7P 853001-82-8P 853001-84-0P
 853001-85-1P 853001-86-2P 853001-87-3P
 853001-88-4P 853001-89-5P 853001-90-8P
 853001-91-9P 853001-92-0P 853001-93-1P
 853001-94-2P 853001-95-3P 853001-96-4P
 853001-97-5P 853002-00-3P 853002-01-4P
 853002-02-5P 853002-03-6P 853002-04-7P
 853002-05-8P 853002-06-9P 853002-07-0P
 853002-08-1P 853002-09-2P 853002-10-5P
 853002-11-6P 853002-12-7P 853002-13-8P
 853002-14-9P 853002-15-0P 853002-16-1P


853002-17-2P 853002-18-3P 853002-19-4P
 853002-20-7P 853002-21-8P 853002-22-9P
 853002-23-0P 853002-24-1P 853002-25-2P
 853002-26-3P 853002-27-4P 853002-28-5P
 853002-29-6P 853002-30-9P 853002-31-0P
 853002-32-1P 853002-33-2P 853002-34-3P
 853002-35-4P 853002-36-5P 853002-37-6P
 853002-38-7P 853002-39-8P 853002-40-1P
 853002-41-2P 853002-42-3P 853002-43-4P
 853002-44-5P 853002-45-6P 853002-46-7P
 853002-47-8P 853002-48-9P 853002-49-0P
 853002-50-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of quinazoline derivs. as erbB2 receptor tyrosine kinase
 inhibitors)

RN 786689-48-3 CAPLUS

CN Phenol, 4-[[5-[(1R)-2-amino-1-methylethoxy]-4-quinazolinyl]amino]-2-chloro-
 (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-66-5 CAPLUS

CN Phenol, 4-[[5-[(1R)-2-amino-1-methylethoxy]-4-quinazolinyl]amino]-2-methyl-
 (CA INDEX NAME)

Absolute stereochemistry.




RN 786689-86-9 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[(1R)-1-

10/ 554,202


methyl-2-(methyl-2-propen-1-ylamino)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 853001-81-7 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(methylamino)ethoxy]- (CA INDEX NAME)




RN 853001-82-8 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[(1R)-1-methyl-2-(methylamino)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 853001-84-0 CAPLUS

CN 4-Quinazolinamine, 5-[(2R)-2-aminopropoxy]-N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 853001-85-1 CAPLUS

CN 4-Quinazolinamine, 5-(2-aminoethoxy)-N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]- (CA INDEX NAME)


10/ 554,202



RN 853001-86-2 CAPLUS
 CN Acetamide, 2-hydroxy-N-[2-[[4-[(4-hydroxy-3-methylphenyl)amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)




RN 853001-87-3 CAPLUS
 CN Phenol, 2-methyl-4-[[5-[2-(methylamino)ethoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 853001-88-4 CAPLUS


CN Acetamide, N-[(2R)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]propyl]-2-methoxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-89-5 CAPLUS

CN Phenol, 2-chloro-4-[[5-[2-(methylamino)ethoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 853001-90-8 CAPLUS


CN Acetamide, N-[2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)



RN 853001-91-9 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-92-0 CAPLUS

CN Phenol, 2-chloro-4-[[5-[(1R)-1-methyl-2-(methyl-2-propen-1-ylamino)ethoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-93-1 CAPLUS

10/ 554,202

CN Phenol, 2-chloro-4-[[5-[(1R)-1-methyl-2-(methylamino)ethoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-94-2 CAPLUS


CN Acetamide, N-[(2R)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 853001-95-3 CAPLUS

CN Acetamide, N-[2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)




10/ 554,202

RN 853001-96-4 CAPLUS


CN Acetamide, N-[(2R)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 853001-97-5 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(ethylamino)ethoxy]- (CA INDEX NAME)



RN 853002-00-3 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(propylamino)ethoxy]- (CA INDEX NAME)

10/ 554,202




RN 853002-01-4 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-[(1-methylethyl)amino]ethoxy]- (CA INDEX NAME)




RN 853002-02-5 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(2-propen-1-ylamino)ethoxy]- (CA INDEX NAME)




RN 853002-03-6 CAPLUS
 CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(cyclopropylamino)ethoxy]- (CA INDEX NAME)




RN 853002-04-7 CAPLUS
 CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-[(cyclopropylmethyl)amino]ethoxy]- (CA INDEX NAME)



RN 853002-05-8 CAPLUS
 CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(cyclobutylamino)ethoxy]- (CA INDEX NAME)




RN 853002-06-9 CAPLUS
 CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-[(1-methyl-4-piperidinyl)amino]ethoxy]- (CA INDEX NAME)



RN 853002-07-0 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-[(tetrahydro-2H-pyran-4-yl)amino]ethoxy]- (CA INDEX NAME)



RN 853002-08-1 CAPLUS


CN Ethanol, 2-[[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]amino]- (CA INDEX NAME)

10/ 554,202



RN 853002-09-2 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-[(2-methoxyethyl)amino]ethoxy]- (CA INDEX NAME)



RN 853002-10-5 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(2-propyn-1-ylamino)ethoxy]- (CA INDEX NAME)


10/ 554,202



RN 853002-11-6 CAPLUS

CN 4-Quinazolinamine, 5-[(1S)-2-amino-1-methylethoxy]-N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853002-12-7 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 853002-13-8 CAPLUS

CN Acetamide, N-[(1R)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-14-9 CAPLUS

CN Phenol, 2-chloro-4-[[5-[(2R)-2-(methylamino)propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853002-15-0 CAPLUS

CN Acetamide, N-[(1R)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-

10/ 554,202

quinazolinyl]oxy]-1-methylethyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-16-1 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-17-2 CAPLUS

CN Phenol, 2-chloro-4-[[5-[(2S)-2-(methylamino)propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




10/ 554,202

RN 853002-18-3 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-19-4 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-methoxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 853002-20-7 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 853002-21-8 CAPLUS

CN Phenol, 4-[[5-[(2S)-2-aminopropoxy]-4-quinazolinyl]amino]-2-chloro- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-22-9 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853002-23-0 CAPLUS

CN 4-Quinazolinamine, 5-[(2S)-2-aminopropoxy]-N-[3-chloro-4-(2-

10/ 554,202

pyridinylmethoxy)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-24-1 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]propyl]-2-(dimethylamino)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-25-2 CAPLUS


CN 4-Quinazolinamine, 5-[(1R)-2-amino-1-methylethoxy]-N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 853002-26-3 CAPLUS


CN 4-Quinazolinamine, 5-(2-aminoethoxy)-N-[3-chloro-4-(4-thiazolylmethoxy)phenyl]- (CA INDEX NAME)



RN 853002-27-4 CAPLUS

CN Phenol, 4-[[5-(2-aminoethoxy)-4-quinazolinyl]amino]-2-chloro- (CA INDEX NAME)


10/ 554,202



RN 853002-28-5 CAPLUS

CN 4-Quinazolinamine, 5-[(2R)-2-aminopropoxy]-N-[3-chloro-4-(4-thiazolylmethoxy)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-29-6 CAPLUS

CN Phenol, 4-[[5-[(2R)-2-aminopropoxy]-4-quinazolinyl]amino]-2-chloro- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-30-9 CAPLUS


CN Acetamide, N-[2-[[4-[(4-hydroxy-3-methylphenyl)amino]-5-

quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)




RN 853002-31-0 CAPLUS

CN Acetamide, 2-hydroxy-N-[2-[[4-[(4-hydroxy-3-methylphenyl)amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)



RN 853002-32-1 CAPLUS

CN Phenol, 4-[[5-(2-aminoethoxy)-4-quinazolinyl]amino]-2-methyl- (CA INDEX NAME)




RN 853002-33-2 CAPLUS

CN Acetamide, N-[2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]-


10/ 554,202

1,1-dimethylethyl]-2-hydroxy- (CA INDEX NAME)



RN 853002-34-3 CAPLUS


CN Phenol, 4-[[5-(2-amino-2-methylpropoxy)-4-quinazolinyl]amino]-2-chloro-
(CA INDEX NAME)



RN 853002-35-4 CAPLUS

CN Acetamide, 2-hydroxy-N-[(2R)-2-[[4-[(4-hydroxy-3-methylphenyl)amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853002-36-5 CAPLUS

10/ 554,202

CN Acetamide, N-[(2R)-2-[[4-[(4-hydroxy-3-methylphenyl)amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-37-6 CAPLUS

CN Acetamide, 2-hydroxy-N-[(2R)-2-[[4-[(4-hydroxy-3-methylphenyl)amino]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 853002-38-7 CAPLUS

CN Phenol, 2-methyl-4-[[5-[(1R)-1-methyl-2-(methyl-2-propen-1-ylamino)ethoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 853002-39-8 CAPLUS

CN Phenol, 2-methyl-4-[[5-[(1R)-1-methyl-2-(methylamino)ethoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-40-1 CAPLUS

CN Acetamide, N-[(1R)-2-[[4-[(4-hydroxy-3-methylphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 853002-41-2 CAPLUS

CN Phenol, 2-methyl-4-[[5-[(2R)-2-(methylamino)propoxy]-4-quinazolinyl]amino]-

(CA INDEX NAME)


Absolute stereochemistry.



RN 853002-42-3 CAPLUS

CN Acetamide, 2-hydroxy-N-[(1R)-2-[[4-[(4-hydroxy-3-methylphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-43-4 CAPLUS

CN 4-Quinazolinamine, 5-[(1R)-1-methyl-2-(methylamino)ethoxy]-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




10/ 554,202

RN 853002-44-5 CAPLUS

CN 4-Quinazolinamine, 5-[(1R)-1-methyl-2-(methyl-2-propen-1-ylamino)ethoxy]-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-45-6 CAPLUS

CN 4-Quinazolinamine, 5-[(1S)-1-methyl-2-(methylamino)ethoxy]-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853002-46-7 CAPLUS

CN 4-Quinazolinamine, 5-[(1S)-1-methyl-2-(methyl-2-propen-1-ylamino)ethoxy]-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 853002-47-8 CAPLUS

CN 4-Quinazolinamine, 5-[(1R)-2-amino-1-methylethoxy]-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-48-9 CAPLUS

CN 4-Quinazolinamine, 5-[(2R)-2-(methylamino)propoxy]-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853002-49-0 CAPLUS

CN 4-Quinazolinamine, 5-[(2S)-2-(methylamino)propoxy]-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (CA INDEX NAME)


methyl-3-pyridinyl)oxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 853002-50-3 CAPLUS

CN 4-Quinazolinamine, 5-[2-(methylamino)ethoxy]-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:927050 CAPLUS

DOCUMENT NUMBER: 141:395568

TITLE: Preparation of (anilino)quinazoline derivatives as antiproliferative agents

INVENTOR(S): Bradbury, Robert Hugh; Kettle, Jason Grant

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 134 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004093880	A1	20041104	WO 2004-GB1713	20040420
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004231349	A1	20041104	AU 2004-231349	20040420
CA 2526897	A1	20041104	CA 2004-2526897	20040420
EP 1631292	A1	20060308	EP 2004-728367	20040420
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009633	A	20060425	BR 2004-9633	20040420
CN 1809360	A	20060726	CN 2004-80017046	20040420
JP 2006524218	T	20061026	JP 2006-506155	20040420
NZ 543015	A	20080131	NZ 2004-543015	20040420
NO 2005004856	A	20051121	NO 2005-4856	20051020
US 20070149546	A1	20070628	US 2005-554202	20051024
PRIORITY APPLN. INFO.:			GB 2003-9009	A 20030422
			WO 2004-GB1713	W 20040420
OTHER SOURCE(S):		MARPAT 141:395568		
GI				



AB Title compds. represented by the formula I [wherein R1, R2 = independently H, carboxy, formyl, etc.; R1a, R2a = independently H or alkyl; R3, R4 = independently H, alkyl, alkenyl; R5 = halo, OH, alkyl, alkoxy, alkenyl,

alkynyl; R6 = H, alkoxy, alkenyloxy, alkynyloxy; X = H, halo, alkyl, alkoxy, alkenyl, alkynyl; Y = O, S, SO₂, etc.; Q1 = Ph, pyridinyl, pyrazinyl, etc.; and pharmaceutically acceptable salts thereof] were prepared as antiproliferative agents. For example, reaction of 2-chloro-4-[[5-[(1R)-2-dimethylamino-1-methylethoxy]quinazolin-4-yl]amino]phenol with 4-(chloromethyl)thiazole•HCl gave II in 20% yield. II showed inhibition of phosphorylation of a tyrosine containing polypeptide substance by ERBB2 kinase (IC₅₀ = 0.002 μ M), EGFR kinase (IC₅₀ = 0.068 μ M) and ERBB2 in a MCF6 (breast carcinoma) derived cell line (IC₅₀ = 0.001 μ M). Thus, I and their pharmaceutical compns. are useful as antiproliferative agents in the production of an ERBB2 receptor tyrosine kinase inhibitory effect in a warm-blooded animal such as man.

IT 786688-99-1P, 4-[3-Chloro-4-(2-pyridylmethoxy)anilino]-5-(2-dimethylaminoethoxy)quinazoline 786689-00-7P, 4-[3-Chloro-4-(2-pyridylmethoxy)anilino]-5-(2-dimethylamino-1-methylethoxy)quinazoline 786689-01-8P, 4-[3-Chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]anilino]-5-(2-dimethylaminoethoxy)quinazoline 786689-03-0P, 4-[3-Chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]anilino]-5-(2-dimethylamino-2-methylethoxy)quinazoline 786689-04-1P, 4-[4-(3-Fluorobenzoyloxy)anilino]-5-(2-dimethylaminoethoxy)quinazoline 786689-06-3P, 4-[4-(3-Fluorobenzoyloxy)anilino]-5-(2-dimethylamino-1-methylethoxy)quinazoline 786689-07-4P, 4-[3-Chloro-4-(2-pyrazinylmethoxy)anilino]-5-(2-dimethylaminoethoxy)quinazoline 786689-11-0P, 4-[3-Chloro-4-(2-pyrazinylmethoxy)anilino]-5-(2-dimethylamino-1-methylethoxy)quinazoline 786689-12-1P, 4-[3-Chloro-4-(5-methylisoxazol-3-ylmethoxy)anilino]-5-(2-dimethylaminoethoxy)quinazoline 786689-15-4P, 4-[3-Chloro-4-(5-methylisoxazol-3-ylmethoxy)anilino]-5-(2-dimethylamino-1-methylethoxy)quinazoline 786689-16-5P, 4-[3-Chloro-4-(3-fluorobenzoyloxy)anilino]-5-[2-(N-ethyl-N-methylamino)ethoxy]quinazoline 786689-17-6P 786689-21-2P, 4-[3-Chloro-4-(3-fluorobenzoyloxy)anilino]-5-(2-dimethylaminoethoxy)quinazoline 786689-22-3P, 4-[3-Chloro-4-(3-fluorobenzoyloxy)anilino]-5-[2-[N-(2-hydroxyethyl)-N-methylamino]ethoxy]quinazoline 786689-23-4P, 4-[3-Chloro-4-(2-pyridylmethoxy)anilino]-5-[2-(N-ethyl-N-methylamino)ethoxy]quinazoline 786689-24-5P 786689-28-9P, 4-[3-Chloro-4-(2-pyridylmethoxy)anilino]-5-[2-[N-(2-hydroxyethyl)-N-methylamino]ethoxy]quinazoline 786689-29-0P 786689-30-3P, 4-[3-Chloro-4-(3-fluorobenzoyloxy)anilino]-5-(2-dimethylamino-2-methylethoxy)quinazoline 786689-31-4P 786689-33-6P, 4-[3-Chloro-4-(2-pyridylmethoxy)anilino]-5-(2-dimethylamino-2-methylethoxy)quinazoline 786689-35-8P, N-[3-Chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]-5-[2-(dimethylamino)ethoxy]quinazolin-4-amine 786689-38-1P, N-[3-Chloro-4-(pyridin-2-yloxy)phenyl]-5-[2-(dimethylamino)ethoxy]quinazolin-4-amine 786689-39-2P, N-[3-Chloro-4-(pyrazin-2-ylmethoxy)phenyl]-5-[[1S]-2-(dimethylamino)-1-methylethyl]oxy]quinazolin-4-amine 786689-41-6P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[1S]-2-(dimethylamino)-1-methylethyl]oxy]quinazolin-4-amine 786689-43-8P, N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[[1R]-2-(dimethylamino)-1-methylethyl]oxy]quinazolin-4-amine 786689-50-7P, N-[3-Chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]-5-[[1R]-2-(dimethylamino)-1-methylethyl]oxy]quinazolin-4-amine 786689-52-9P, N-[3-Chloro-4-(pyrazin-2-ylmethoxy)phenyl]-5-[[1R]-2-(dimethylamino)-1-methylethyl]oxy]quinazolin-4-amine 786689-54-1P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[1R]-2-(dimethylamino)-1-methylethyl]oxy]quinazolin-4-amine 786689-55-2P, N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[2-(dimethylamino)-2-methylpropoxy]quinazolin-4-amine 786689-57-4P,

N-[3-Chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]-5-[2-(dimethylamino)-2-methylpropoxy]quinazolin-4-amine 786689-58-5P,
 N-[3-Chloro-4-[(5-methylisoxazol-3-yl)methoxy]phenyl]-5-[2-(dimethylamino)-2-methylpropoxy]quinazolin-4-amine 786689-59-6P,
 5-[2-(Dimethylamino)ethoxy]-N-[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine 786689-62-1P,
 5-[2-(Dimethylamino)ethoxy]-N-[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]quinazolin-4-amine 786689-63-2P,
 5-[2-(Dimethylamino)ethoxy]-N-[3-methyl-4-[(5-methylisoxazol-3-yl)methoxy]phenyl]quinazolin-4-amine 786689-64-3P,
 5-[[(1R)-2-(Dimethylamino)-1-methylethyl]oxy]-N-[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine 786689-67-6P,
 5-[[(1R)-2-(Dimethylamino)-1-methylethyl]oxy]-N-[3-methyl-4-(pyrazin-2-ylmethoxy)phenyl]quinazolin-4-amine 786689-68-7P,
 5-[[(1R)-2-(Dimethylamino)-1-methylethyl]oxy]-N-[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]quinazolin-4-amine 786689-69-8P,
 5-[[(1R)-2-(Dimethylamino)-1-methylethyl]oxy]-N-[3-methyl-4-[(5-methylisoxazol-3-yl)methoxy]phenyl]quinazolin-4-amine 786689-70-1P
 , 5-[2-(Dimethylamino)-2-methylpropoxy]-N-[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]quinazolin-4-amine 786689-72-3P,
 5-[2-(Dimethylamino)ethoxy]-N-[3-methoxy-4-[(5-methylisoxazol-3-yl)methoxy]phenyl]quinazolin-4-amine 786689-75-6P,
 5-[2-(Dimethylamino)ethoxy]-N-[3-methoxy-4-(pyrazin-2-ylmethoxy)phenyl]quinazolin-4-amine 786689-76-7P,
 5-[2-(Dimethylamino)ethoxy]-N-[3-fluoro-4-(1,3-thiazol-5-ylmethoxy)phenyl]quinazolin-4-amine 786689-79-0P,
 N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[[(1S)-2-(dimethylamino)-1-methylethyl]oxy]quinazolin-4-amine 786689-80-3P,
 N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[[(2S)-2-(dimethylamino)propyl]oxy]quinazolin-4-amine 786689-81-4P,
 N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[[(2R)-2-(dimethylamino)propyl]oxy]quinazolin-4-amine 786689-82-5P,
 5-[2-[Allyl(methyl)amino]ethoxy]-N-[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine 786689-83-6P,
 2-[[2-[[4-[[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]amino]quinazolin-5-yl]oxy]ethyl](ethyl)amino]ethanol 786689-84-7P,
 N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[[(1S)-2-[(2-methoxyethyl)(methyl)amino]-1-methylethyl]oxy]quinazolin-4-amine dihydrochloride 786689-85-8P, N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[[(1R)-2-[ethyl(methyl)amino]-1-methylethyl]oxy]quinazolin-4-amine dihydrochloride 786689-86-9P,
 5-[[(1R)-2-[Allyl(methyl)amino]-1-methylethyl]oxy]-N-[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine 786689-87-0P,
 5-[[(1S)-2-[Allyl(methyl)amino]-1-methylethyl]oxy]-N-[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine 786689-88-1P,
 N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[(2S)-2-(dimethylamino)propyl]oxy]quinazolin-4-amine 786689-89-2P,
 N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[(2R)-2-(dimethylamino)propyl]oxy]quinazolin-4-amine 786689-90-5P,
 N-[3-Chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]-5-[[(2S)-2-(dimethylamino)propyl]oxy]quinazolin-4-amine 786689-91-6P,
 N-[3-Chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]-5-[[(2R)-2-(dimethylamino)propyl]oxy]quinazolin-4-amine hydrochloride 786689-92-7P, N-[3-Chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]-5-[[(1R)-2-(dimethylamino)-1-methylethyl]oxy]quinazolin-4-amine dihydrochloride 786689-93-8P, 5-[2-(Dimethylamino)-1-methylethoxy]-N-(3-methoxy-4-phenoxyphenyl)quinazolin-4-amine 786689-95-0P, N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[2-(dimethylamino)-1,1-dimethylethoxy]quinazolin-4-amine 786689-96-1P 786689-97-2P, N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[[(1S)-


2-[(2-methoxyethyl)(methyl)amino]-1-methylethyl]oxy]quinazolin-4-amine
 786689-99-4P, N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[[(1R)-
 2-[ethyl(methyl)amino]-1-methylethyl]oxy]quinazolin-4-amine
 786690-00-4P, N-[3-Chloro-4-[(1-methyl-1H-imidazol-2-
 yl)thio]phenyl]-5-[[(2R)-2-(dimethylamino)propyl]oxy]quinazolin-4-amine
 786690-01-5P, N-[3-Chloro-4-[(1-methyl-1H-imidazol-2-
 yl)thio]phenyl]-5-[[(R)-2-(dimethylamino)-1-methylethyl]oxy]quinazolin-4-
 amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of 4-anilino-quinazoline derivs. as antiproliferative agents)

RN 786688-99-1 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-
 (dimethylamino)ethoxy]- (CA INDEX NAME)



RN 786689-00-7 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-
 (dimethylamino)-1-methylethoxy]- (CA INDEX NAME)

10/ 554,202



RN 786689-01-8 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]-5-[2-(dimethylamino)ethoxy]- (CA INDEX NAME)



RN 786689-03-0 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]-5-[2-(dimethylamino)propoxy]- (CA INDEX NAME)

10/ 554,202



RN 786689-04-1 CAPLUS


CN 4-Quinazolinamine, 5-[2-(dimethylamino)ethoxy]-N-[4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)




RN 786689-06-3 CAPLUS

CN 4-Quinazolinamine, 5-[2-(dimethylamino)-1-methylethoxy]-N-[4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)

10/ 554,202




RN 786689-07-4 CAPLUS
CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyrazinylmethoxy)phenyl]-5-[2-(dimethylamino)ethoxy]- (CA INDEX NAME)




RN 786689-11-0 CAPLUS
CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyrazinylmethoxy)phenyl]-5-[2-(dimethylamino)-1-methylethoxy]- (CA INDEX NAME)

10/ 554,202



RN 786689-12-1 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-[(5-methyl-3-isoxazolyl)methoxy]phenyl]-5-[2-(dimethylamino)ethoxy]- (CA INDEX NAME)



RN 786689-15-4 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-[(5-methyl-3-isoxazolyl)methoxy]phenyl]-5-[2-(dimethylamino)ethoxy]- (CA INDEX NAME)

10/ 554,202



RN 786689-16-5 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(ethylmethylamino)ethoxy]- (CA INDEX NAME)



RN 786689-17-6 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(ethylmethylamino)ethoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 786689-16-5

CMF C26 H26 Cl F N4 O2


10/ 554,202



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 786689-21-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(dimethylamino)ethoxy]- (CA INDEX NAME)




RN 786689-22-3 CAPLUS

CN Ethanol, 2-[[2-[[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]methylamino]- (CA INDEX NAME)



RN 786689-23-4 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(ethylmethylamino)ethoxy]- (CA INDEX NAME)



RN 786689-24-5 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(ethylmethylamino)ethoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 786689-23-4


10/ 554,202

CMF C25 H26 Cl N5 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 786689-28-9 CAPLUS
CN Ethanol, 2-[[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]methylamino]- (CA INDEX NAME)


10/ 554,202



RN 786689-29-0 CAPLUS
CN Ethanol, 2-[[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]methylamino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 786689-28-9
CMF C25 H26 Cl N5 O3



CM 2


CRN 76-05-1
CMF C2 H F3 O2

10/ 554,202



RN 786689-30-3 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(dimethylamino)propoxy]- (CA INDEX NAME)



RN 786689-31-4 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(dimethylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 786689-30-3

CMF C26 H26 Cl F N4 O2


10/ 554,202



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 786689-33-6 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(dimethylamino)propoxy]- (CA INDEX NAME)

10/ 554,202



RN 786689-35-8 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-(4-thiazolylmethoxy)phenyl]-5-[2-(dimethylamino)ethoxy]- (CA INDEX NAME)



RN 786689-38-1 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinyloxy)phenyl]-5-[2-(dimethylamino)ethoxy]- (CA INDEX NAME)


10/ 554,202



RN 786689-39-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyrazinylmethoxy)phenyl]-5-[(1S)-2-(dimethylamino)-1-methylethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-41-6 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[(1S)-2-(dimethylamino)-1-methylethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-43-8 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[(1R)-2-(dimethylamino)-1-methylethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-50-7 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(4-thiazolylmethoxy)phenyl]-5-[(1R)-2-(dimethylamino)-1-methylethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




10/ 554,202

RN 786689-52-9 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyrazinylmethoxy)phenyl]-5-[(1R)-2-(dimethylamino)-1-methylethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-54-1 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[(1R)-2-(dimethylamino)-1-methylethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 786689-55-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(dimethylamino)-2-methylpropoxy]- (CA INDEX NAME)




RN 786689-57-4 CAPLUS
 CN 4-Quinazolinamine, N-[3-chloro-4-(4-thiazolylmethoxy)phenyl]-5-[2-(dimethylamino)-2-methylpropoxy]- (CA INDEX NAME)




RN 786689-58-5 CAPLUS
 CN 4-Quinazolinamine, N-[3-chloro-4-[(5-methyl-3-isoxazolyl)methoxy]phenyl]-5-[2-(dimethylamino)-2-methylpropoxy]- (CA INDEX NAME)

10/ 554,202



RN 786689-59-6 CAPLUS


CN 4-Quinazolinamine, 5-[2-(dimethylamino)ethoxy]-N-[3-methyl-4-(2-pyridinylmethoxy)phenyl]- (CA INDEX NAME)



RN 786689-62-1 CAPLUS


CN 4-Quinazolinamine, 5-[2-(dimethylamino)ethoxy]-N-[3-methyl-4-(4-thiazolylmethoxy)phenyl]- (CA INDEX NAME)

10/ 554,202



RN 786689-63-2 CAPLUS


CN 4-Quinazolinamine, 5-[2-(dimethylamino)ethoxy]-N-[3-methyl-4-[(5-methyl-3-isoxazolyl)methoxy]phenyl]- (CA INDEX NAME)



RN 786689-64-3 CAPLUS

CN 4-Quinazolinamine, 5-[(1R)-2-(dimethylamino)-1-methylethoxy]-N-[3-methyl-4-(2-pyridinylmethoxy)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-67-6 CAPLUS

CN 4-Quinazolinamine, 5-[(1R)-2-(dimethylamino)-1-methylethoxy]-N-[3-methyl-4-(2-pyrazinylmethoxy)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-68-7 CAPLUS

CN 4-Quinazolinamine, 5-[(1R)-2-(dimethylamino)-1-methylethoxy]-N-[3-methyl-4-(4-thiazolylmethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




10/ 554,202

RN 786689-69-8 CAPLUS


CN 4-Quinazolinamine, 5-[(1R)-2-(dimethylamino)-1-methylethoxy]-N-[3-methyl-4-[(5-methyl-3-isoxazolyl)methoxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 786689-70-1 CAPLUS

CN 4-Quinazolinamine, 5-[2-(dimethylamino)-2-methylpropoxy]-N-[3-methyl-4-(4-thiazolylmethoxy)phenyl]- (CA INDEX NAME)




RN 786689-72-3 CAPLUS

CN 4-Quinazolinamine, 5-[2-(dimethylamino)ethoxy]-N-[3-methoxy-4-[(5-methyl-3-isoxazolyl)methoxy]phenyl]- (CA INDEX NAME)



RN 786689-75-6 CAPLUS


CN 4-Quinazolinamine, 5-[2-(dimethylamino)ethoxy]-N-[3-methoxy-4-(2-pyrazinylmethoxy)phenyl]- (CA INDEX NAME)



RN 786689-76-7 CAPLUS

CN 4-Quinazolinamine, 5-[2-(dimethylamino)ethoxy]-N-[3-fluoro-4-(5-thiazolylmethoxy)phenyl]- (CA INDEX NAME)


10/ 554,202



RN 786689-79-0 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[(1S)-2-(dimethylamino)-1-methylethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-80-3 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[(2S)-2-(dimethylamino)propoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-81-4 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[(2R)-2-(dimethylamino)propoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-82-5 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(methyl-2-propen-1-ylamino)ethoxy]- (CA INDEX NAME)

10/ 554,202



RN 786689-83-6 CAPLUS


CN Ethanol, 2-[[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]ethylamino]- (CA INDEX NAME)



RN 786689-84-7 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[(1S)-2-[(2-methoxyethyl)methylamino]-1-methylethoxy]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 786689-85-8 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[(1R)-2-(ethylmethylamino)-1-methylethoxy]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 786689-86-9 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[(1R)-1-methyl-2-(methyl-2-propen-1-ylamino)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-87-0 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[(1S)-1-methyl-2-(methyl-2-propen-1-ylamino)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-88-1 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[(2S)-2-(dimethylamino)propoxy]- (CA INDEX NAME)

Absolute stereochemistry.




10/ 554,202

RN 786689-89-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[(2R)-2-(dimethylamino)propoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-90-5 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]-5-[(2S)-2-(dimethylamino)propoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 786689-91-6 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]-5-[(2R)-2-(dimethylamino)propoxy]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



● HCl


RN 786689-92-7 CAPLUS
CN 4-Quinazolinamine, N-[3-chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]-5-[(1R)-2-(dimethylamino)-1-methylethoxy]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 786689-93-8 CAPLUS
CN 4-Quinazolinamine, 5-[2-(dimethylamino)-1-methylethoxy]-N-(3-methoxy-4-phenoxyphenyl)- (CA INDEX NAME)



RN 786689-95-0 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(dimethylamino)-1,1-dimethylethoxy]- (CA INDEX NAME)



RN 786689-96-1 CAPLUS

CN 4-Quinazolinamine, 5-[2-(dimethylamino)ethoxy]-N-(3-methoxy-4-phenoxyphenyl)- (CA INDEX NAME)


10/ 554,202



RN 786689-97-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[(1S)-2-[(2-methoxyethyl)methylamino]-1-methylethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-99-4 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[(1R)-2-(ethylmethylamino)-1-methylethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786690-00-4 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]-
5-[(2R)-2-(dimethylamino)propoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786690-01-5 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]-
5-[(1R)-2-(dimethylamino)-1-methylethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



IT 786689-36-9P, 2-Chloro-4-[[5-[2-(dimethylamino)ethoxy]quinazolin-4-yl]amino]phenol 786689-40-5P, 2-Chloro-4-[[5-[[1S]-2-(dimethylamino)-1-methylethyl]oxy]quinazolin-4-yl]amino]phenol 786689-45-0P, 2-Chloro-4-[[5-[[1R]-2-(dimethylamino)-1-methylethyl]oxy]quinazolin-4-yl]amino]phenol 786689-48-3P, 4-[[5-[[1R]-2-Amino-1-methylethyl]oxy]quinazolin-4-yl]amino]-2-chlorophenol 786689-56-3P, 2-Chloro-4-[[5-[2-(dimethylamino)-2-methylpropoxy]quinazolin-4-yl]amino]phenol 786689-60-9P, 4-[[5-[2-(Dimethylamino)ethoxy]quinazolin-4-yl]amino]-2-methylphenol 786689-65-4P, 4-[[5-[[1R]-2-(Dimethylamino)-1-methylethyl]oxy]quinazolin-4-yl]amino]-2-methylphenol 786689-66-5P, 4-[[5-[[1R]-2-Amino-1-methylethyl]oxy]quinazolin-4-yl]amino]-2-methylphenol 786689-71-2P, 4-[[5-[2-(Dimethylamino)-2-methylpropoxy]quinazolin-4-yl]amino]-2-methylphenol 786689-73-4P, 4-[[5-[2-(Dimethylamino)ethoxy]quinazolin-4-yl]amino]-2-methoxyphenol 786689-77-8P, 4-[[5-[2-(Dimethylamino)ethoxy]quinazolin-4-yl]amino]-2-fluorophenol


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of 4-anilino-quinazoline derivs. as antiproliferative agents)

RN 786689-36-9 CAPLUS


CN Phenol, 2-chloro-4-[[5-[2-(dimethylamino)ethoxy]-4-quinazolinyl]amino]-
(CA INDEX NAME)



RN 786689-40-5 CAPLUS

CN Phenol, 2-chloro-4-[[5-[(1S)-2-(dimethylamino)-1-methylethoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 786689-45-0 CAPLUS

CN Phenol, 2-chloro-4-[[5-[(1R)-2-(dimethylamino)-1-methylethoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.


10/ 554,202



RN 786689-48-3 CAPLUS


CN Phenol, 4-[[5-[(1R)-2-amino-1-methylethoxy]-4-quinazolinyl]amino]-2-chloro-
(CA INDEX NAME)

Absolute stereochemistry.



RN 786689-56-3 CAPLUS


CN Phenol, 2-chloro-4-[[5-[2-(dimethylamino)-2-methylpropoxy]-4-quinazolinyl]amino]-
(CA INDEX NAME)



RN 786689-60-9 CAPLUS

CN Phenol, 4-[[5-[2-(dimethylamino)ethoxy]-4-quinazolinyl]amino]-2-methyl-
(CA INDEX NAME)


10/ 554,202



RN 786689-65-4 CAPLUS

CN Phenol, 4-[[5-[(1R)-2-(dimethylamino)-1-methylethoxy]-4-quinazolinyl]amino]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-66-5 CAPLUS

CN Phenol, 4-[[5-[(1R)-2-amino-1-methylethoxy]-4-quinazolinyl]amino]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-71-2 CAPLUS


10/ 554,202

CN Phenol, 4-[[5-[2-(dimethylamino)-2-methylpropoxy]-4-quinazolinyl]amino]-2-methyl- (CA INDEX NAME)




RN 786689-73-4 CAPLUS

CN Phenol, 4-[[5-[2-(dimethylamino)ethoxy]-4-quinazolinyl]amino]-2-methoxy- (CA INDEX NAME)



RN 786689-77-8 CAPLUS

CN Phenol, 4-[[5-[2-(dimethylamino)ethoxy]-4-quinazolinyl]amino]-2-fluoro- (CA INDEX NAME)



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

10/ 554,202

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:10:44 ON 02 SEP 2008)

FILE 'REGISTRY' ENTERED AT 14:11:00 ON 02 SEP 2008

L1 STRUCTURE UPLOADED

L2 411 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:11:37 ON 02 SEP 2008

L3 9 S L2

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

49.53

228.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-7.20

-7.20

STN INTERNATIONAL LOGOFF AT 14:12:17 ON 02 SEP 2008